September 25, 2013 | A Pacific Biosciences-Roche deal announced today has PacBio stock leaping. The deal gives Roche worldwide exclusive rights to in vitro diagnostics products based on PacBio's SMRT technology for $35 million up front and up to $40 million in milestone payments. Motley Fool